Our Products
The product portfolio is led by already commercialized Binosto® for the treatment of postmenopausal osteoporosis.
EffRx Pharmaceuticals Signs Exclusive Licensing Agreement With Radius Health To Commercialize BINOSTO® In The United States
Freienbach, September 19th, 2023 – EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the development and commercialization of musculoskeletal and rare diseases medications, today announced …
World Orphan Drug Alliance (WODA) Marks their First Anniversary
To read more click title
Abiogen Pharma Completes the Acquisition of EffRx
EffRx Pharmaceuticals SA joins forces with Abiogen Pharma S.p.A. Read PR: Abiogen & EffRx Press Release